Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug 12;2015(8):CD010849.
doi: 10.1002/14651858.CD010849.pub2.

Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease

Norita Hussein  1 , Stephen F Weng, Joe Kai, Jos Kleijnen, Nadeem Qureshi
Affiliations

Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease

Norita Hussein et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Globally, about five per cent of children are born with congenital or genetic disorders. The most common autosomal recessive conditions are thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease, with higher carrier rates in specific patient populations. Identifying and counselling couples at genetic risk of the conditions before pregnancy enables them to make fully informed reproductive decisions, with some of these choices not being available if genetic counselling is only offered in an antenatal setting.

Objectives: To assess the effectiveness of systematic preconception genetic risk assessment to improve reproductive outcomes in women and their partners who are identified as carriers of thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease in healthcare settings when compared to usual care.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Registers. In addition, we searched for all relevant trials from 1970 (or the date at which the database was first available if after 1970) to date using electronic databases (MEDLINE, Embase, CINAHL, PsycINFO), clinical trial databases (National Institutes of Health, Clinical Trials Search portal of the World Health Organization, metaRegister of controlled clinical trials), and hand searching of key journals and conference abstract books from 1998 to date (European Journal of Human Genetics, Genetics in Medicine, Journal of Community Genetics). We also searched the reference lists of relevant articles, reviews and guidelines and also contacted subject experts in the field to request any unpublished or other published trials.Date of latest search of the registers: 25 June 2015.Date of latest search of all other sources: 10 December 2014.

Selection criteria: Any randomised or quasi-randomised control trials (published or unpublished) comparing reproductive outcomes of systematic preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease when compared to usual care.

Data collection and analysis: We identified 19 papers, describing 13 unique trials which were potentially eligible for inclusion in the review. However, after assessment, no randomised controlled trials of preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease were found.

Main results: No randomised controlled trials of preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease were found.

Authors' conclusions: As no randomised controlled trials of preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease were found for inclusion in this review, the research evidence for current policy recommendations is limited to non-randomised studies.Information from well-designed, adequately powered, randomised trials is desirable in order to make more robust recommendations for practice. However, such trials must also consider the legal, ethical, and cultural barriers to implementation of preconception genetic risk assessment.

PubMed Disclaimer

Conflict of interest statement

Dr Nadeem Qureshi and Dr Joe Kai are investigators on a UK National Institute of Health research project evaluating preconception screening in primary care and plan to pursue further research in this area. Dr Qureshi is also collaborating on a project to evaluate the evidence base relevant to NICE guidelines behind primary care.

Professor Jos Kleijnen declares Kleijnen Systematic Reviews Ltd has received project funding from various pharmaceutical companies for work in unrelated areas.

For the remaining authors there are no known declarations of interest.

Figures

Figure 1
Figure 1
Study flow diagram
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies excluded from this review

    1. Alhamdan NA, Almazrou YY, Alswaidi FM, Choudhry AJ. Premarital screening for thalassemia and sickle cell disease in Saudi Arabia. Genetics in Medicine 2007;9(6):372‐7. - PubMed
    1. Bekker H, Modell M, Denniss G, Silver A, Mathew C, Bobrow M, Marteau T. Uptake of cystic fibrosis testing in primary care: supply push or demand pull?. British Medical Journal 1993;306(6892):1584‐6. - PMC - PubMed
    1. Castellani C, Perobelli S, Bianchi V, Seia M, Melotti P, Zanolla L, et al. An interactive computer program can effectively educate potential users of cystic fibrosis carrier tests. American Journal of Medical Genetics 2011;155A(4):778‐85. - PubMed
    1. Callanan NP, Cheuvront B, Sorenson JR. CF Carrier testing in a high risk population: Anxiety,risk perceptions, and reproductive plans of carrier by "non‐carrier'' couples. Genetics in Medicine 1999;1(7):323‐7. - PubMed
    2. Cheuvront B, Sorenson JR, Callanan NP, Stearns SC, DeVellis BM. Psychosocial and educational outcomes associated with home‐ and clinic‐based pretest education and cystic fibrosis carrier testing among a population of at‐risk relatives. American Journal of Medical Genetics 1998;75(5):461‐8. - PubMed
    1. Childs B, Gordis L, Kaback MM, Kazazian HH. Tay‐Sachs screening: motives for participating and knowledge of genetics and probability. American Journal of Human Genetics 1976;28(6):537‐49. - PMC - PubMed
    2. Childs B, Gordis L, Kaback MM, Kazazian HH. Tay‐Sachs screening: social and psychological impact. American Journal of Human Genetics 1976;28(6):550‐8. - PMC - PubMed

Additional references

    1. Abbot J, Dodd M, Webb AK. Health perceptions and treatment adherence in adults with cystic fibrosis. Thorax 1996;51(12):1233‐8. - PMC - PubMed
    1. American College of Obstetricians and Gynecologists. Screening for Tay‐Sachs disease. ACOG Committee Opinion No. 318. Obstetrics & Gynecology 2005;106:893‐4. - PubMed
    1. American College of Obstetricians and Gynecologists. Preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent. ACOG Committee Opinion No. 442 Obstetrics & Gynecology2009; Vol. 114:950‐3. - PubMed
    1. Alswaidi FM, O'Brien SJ. Premarital screening programmes for haemoglobinopathies, HIV and hepatitis viruses: review and factors affecting their success. Journal of Medical Screening 2009;16(1):22‐8. - PubMed
    1. Alwan A, Modell B. Community control of genetic and congenital disorders. EMRO Technical Publication 24. Alexandria: Eastern Mediterranean Regional Office: World Health Organization, 1997.

Publication types